Liver-kidney recipients with chronic viral hepatitis C treated with interferon-alpha. Hassan, Q., Roche, B., Buffet, C., Bessede, T., Samuel, D., Charpentier, B., & Durrbach, A. Transpl Int, 25(9):941–7, September, 2012.
Liver-kidney recipients with chronic viral hepatitis C treated with interferon-alpha [link]Paper  abstract   bibtex   
Antiviral therapy with interferon-alpha (IFN-alpha) and pegylated IFN-alpha (PEG-IFN-alpha) for chronic hepatitis C (HCV)-infected kidney recipients remains controversial. IFN-alpha is not recommended in most cases because it induces severe acute graft rejection. However, IFN-alpha, as PEG-IFN-alpha, is associated with a more pronounced immune response, and is well tolerated in HCV-infected liver recipients without causing graft rejection. In combined liver-kidney transplant (LKT) recipients, IFN-alpha has been occasionally used and appears to be well tolerated. All LKT recipients with a functioning kidney and liver having a HCV replication and who needed IFN-alpha therapy have been included in the study. The occurrence of liver and/or renal acute rejection as well as the HCV replication has been collected. A total of 12 LKT patients treated with PEG-IFN-alpha plus ribavirin have been studied. No acute rejection was observed. Renal function remained stable during and after discontinuing treatment, without any graft dysfunction. Two patients had a partial viral response and four had a sustained viral response. All patients, whatever their viral response, had decreased liver-enzyme levels. Response to PEG-IFN-alpha therapy was correlated with steroid dose and transaminase level when PEG-IFN-alpha was started. These data suggest that the combination therapy of PEG-IFN-alpha plus ribavirin did not have a higher risk of acute kidney-graft rejection after liver-kidney transplantation.
@article{hassan_liver-kidney_2012,
	title = {Liver-kidney recipients with chronic viral hepatitis {C} treated with interferon-alpha},
	volume = {25},
	issn = {1432-2277 (ELECTRONIC) 0934-0874 (LINKING)},
	shorttitle = {Liver-kidney recipients with chronic viral hepatitis {C} treated with interferon-alpha},
	url = {http://www.ncbi.nlm.nih.gov/pubmed/22882335},
	abstract = {Antiviral therapy with interferon-alpha (IFN-alpha) and pegylated IFN-alpha (PEG-IFN-alpha) for chronic hepatitis C (HCV)-infected kidney recipients remains controversial. IFN-alpha is not recommended in most cases because it induces severe acute graft rejection. However, IFN-alpha, as PEG-IFN-alpha, is associated with a more pronounced immune response, and is well tolerated in HCV-infected liver recipients without causing graft rejection. In combined liver-kidney transplant (LKT) recipients, IFN-alpha has been occasionally used and appears to be well tolerated. All LKT recipients with a functioning kidney and liver having a HCV replication and who needed IFN-alpha therapy have been included in the study. The occurrence of liver and/or renal acute rejection as well as the HCV replication has been collected. A total of 12 LKT patients treated with PEG-IFN-alpha plus ribavirin have been studied. No acute rejection was observed. Renal function remained stable during and after discontinuing treatment, without any graft dysfunction. Two patients had a partial viral response and four had a sustained viral response. All patients, whatever their viral response, had decreased liver-enzyme levels. Response to PEG-IFN-alpha therapy was correlated with steroid dose and transaminase level when PEG-IFN-alpha was started. These data suggest that the combination therapy of PEG-IFN-alpha plus ribavirin did not have a higher risk of acute kidney-graft rejection after liver-kidney transplantation.},
	number = {9},
	journal = {Transpl Int},
	author = {Hassan, Q. and Roche, B. and Buffet, C. and Bessede, T. and Samuel, D. and Charpentier, B. and Durrbach, A.},
	month = sep,
	year = {2012},
	keywords = {Acute, Adult, Aged, Agents/therapeutic, Biopsy, C/*immunology/*virology, Failure/*therapy/virology, Female, Graft, Hepatitis, Humans, Immunosuppressive, Insufficiency/*therapy/virology, Interferon-alpha/*therapeutic, Kidney, Liver, Liver/pathology, Male, Middle, Outcome, Recurrence, Rejection, Renal, Retrospective, Ribavirin/*therapeutic, Steroids/therapeutic, Studies, Transaminases/metabolism, Transplantation/*methods, Treatment, disease, use},
	pages = {941--7}
}

Downloads: 0